DiaMedica-Logo.png
DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
March 19, 2019 16:30 ET | DiaMedica Therapeutics Inc.
Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase II studies in 2H 2019Acute ischemic stroke Phase II...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
March 18, 2019 13:56 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 18, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March...
DiaMedica-Logo.png
DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
March 12, 2019 13:00 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
January 22, 2019 07:45 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announces the publication of a paper titled  “Human Tissue Kallikrein In The Treatment Of Acute Ischemic...
DiaMedica-Logo.png
UPDATE -- DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
January 03, 2019 10:41 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted...
DiaMedica-Logo.png
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
January 03, 2019 07:30 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted...
DiaMedica-Logo.png
DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING
December 07, 2018 07:00 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX‑V:DMA), a clinical stage biopharmaceutical company, announced today the pricing of its...
DiaMedica-Logo.png
DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
November 12, 2018 16:45 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 12, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX Venture:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, announced today that it has applied to list...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
November 06, 2018 17:00 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 06, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its Annual...
DiaMedica-Logo.png
DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
September 05, 2018 08:00 ET | DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) announces the recent appointment of Harry Alcorn Jr. Pharm.D. as...